10/27/2026
Today we announce a strategic partnership with VivaMed BioPharma to advance existing drugs and promising compounds for new applications in cancer based on the underlying molecular interactions of the tumor. Together, we aim to build the computational and clinical evidence needed to bring these treatments to market for the patients most likely to benefit.
The partnership brings together VivaMed’s BioAtlas platform, which maps disease biology and therapeutic opportunities, with Genomate®, which evaluates treatments in the full molecular context of a patient’s cancer. The aim is to use that combined understanding to reveal new possibilities for medicines and guide their development toward the patients most likely to benefit.
As our Chief Executive Officer, Nabil Hafez, explains: “Genomate has pioneered technology to help thousands of patients find the targeted therapy they are most likely to respond to, with our latest model and ever-growing datasets, we now have an opportunity to make the greatest impact to patients by helping bring to market promising compounds.”
Read the full press release: https://www.genomate.health/news-article/genomate-and-vivamed-to-rescue-and-repurpose-oncology-drugs-with-ai-and-clinical-data
For patients, our long-term ambition is a wider range of approved treatment options, including drugs that might otherwise never be developed for their cancer. For drug developers, the partnership offers a data-driven route to new indications, helping to de-risk development and focus investment where the evidence of benefit is strongest.
